baber/WOPTO huggingface dataset:
Patent NZ-527917-A (NZ)
Title: Polycycoalkylpurines as adenosine receptor antagonists
Inventor: KIESMAN WILLIAM F
IPC: C07D473/06
Filed: 2000-11-13
Abstract: A polycycloalkylpurine derivative of formula (I) is disclosed, wherein: R1 and R2 are independently hydrogen, or optionally substituted alkyl, alkenyl, alkynyl or aryl; R3 is an optionally substituted tricyclic group of formula (II); X1 and X2 are independently O or S; Z is a single bond, -O-, -(CH2)1-3-, -O(CH2)1-2-, -CH2OCH2-, -(CH2)1-2O-, -CH=CHCH2-, -CH=CH- or -CH2CH=CH- and R6 is hydrogen, alkyl, acyl, alkylsulphonyl, aralkyl, substituted aralkyl or substituted alkyl or heterocyclyl. These compounds are useful in treating a condition characterized by an elevated adenosine concentration and/or increased sensitivity to adenosine such as cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, diseases for which diuretic treatment is indicated, Parkinson's disease, depression, traumatic brain damage, post-stroke neurological deficit, respiratory depression, neonatal brain trauma, dyslexia, hyperactivity, cystic fibrosis, neonatal apnea, renal failure, diabetes, asthma, or edematous conditions. (62) Divided Out of 519426
Patent NZ-528901-A (NZ)
Title: Multi-functional base for a plastic wide-mouth, blow-molded container
Inventor: TOBIAS JOHN W
IPC: B65D79/00
Filed: 2002-04-16
Abstract: A blow moulded container (10) having a multi-functional base (12) which enables use of the container in both hot-fill operations and pasteurization/retort operations and enables efficient vertical stacking of like containers. To this end, a portion of the base is capable of flexing upwardly and/or downwardly in response to variations in pressures in a filled and sealed container. Structurally, the base has a discontinuous concave outer annular wall (28) forming a discontinuous standing ring (38) and an inner annular wall (40) functioning as a flex panel. The inner annular wall connects outwardly to a plurality of radial webs (46) extending at an elevation above the standing ring and connects inwardly to an anti-inverting, upwardly-projecting dome (48). Preferably, a shoulder (56) extends radially inward on the inward facing side (36) of the outer annular wall above a level of the standing ring to facilitate vertical stacking of containers having like bases.
Patent NZ-530380-A (NZ)
Title: Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
Inventor: WILCOX GLENN ERNEST
IPC: C07D487/04
Filed: 2002-05-29
Abstract: A method for effecting chiral salt resolution from racemic mixtures of enantiomers and particularly precursor enantiomers used in making pyrrolo[2,3-d]pyrimidine compounds, which are inhibitors of protein kinases. Also disclosed are pyrrolo[2,3-d]pyrimidine compounds, such as the compound of formula (I) and the compound 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile, and methods of using such compounds as inhibitors of protein kinases, such as the enzyme Janus Kinase 3.
Patent NZ-535591-A (NZ)
Title: Oxazolidinone derivatives, processes for their preparation, and pharmaceutical compositions containing them
Inventor: GRAVESTOCK MICHEAL BARRY
IPC: A61K/
Filed: 2003-02-25
Abstract: Disclosed are compounds of formula (I), wherein; -N-HET is selected from (Ic), (Id) and (If), Q is a substituted phenyl or pyridyl moiety, and the remaining substituents are defined herein. The compounds are used for the manufacture of medicaments for use as antibacterials.
Patent NZ-535698-A (NZ)
Title: An cryptosystem involving generating an isogeny that maps points from one elliptic curve onto another elliptic curve and publishing a public key corresponding to the isogeny
Inventor: JAO DAVID Y
IPC: G09C1/00
Filed: 2004-10-01
Abstract: Techniques are disclosed to provide public-key encryption systems. More particularly, isogenies of Abelian varieties (e.g., elliptic curves in one dimensional cases) are utilized to provide public-key encryption systems. For example, the isogenies permit the use of multiple curves instead of a single curve to provide more secure encryption. The techniques may be applied to digital signatures and/or identity based encryption (IBE) solutions. The technique of providing public-key encryption includes the method of generating an isogeny that maps a plurality of points from a first elliptic curve onto a second elliptic curve. Composing a plurality of modular isogenies provides the isogeny without revealing any intermediate curves. The public-key corresponding to the isogeny is thus published. A message is encrypted and decrypted using an encryption-key that corresponds to the isogeny, where one of the encryption or decryption keys is a private key that is a dual isogeny of the isogeny.
Patent NZ-543135-A (NZ)
Title: RTP payload format data structure
Inventor: ALKOVE JAMES M
IPC: H04N21/6437
Filed: 2004-06-02
Abstract: Advanced System Format (ASF) mixed media data is translated into enhanced Real Time Transport Protocol packet data for transmission through networks and eventual decryption and rendering. The enhanced protocol or data structure includes a plurality of single media packets (RTP Packets) 110, 112(1), 112(N), 116 which are formed from plural mixed media packets (ASF packets) 106, 108 that have a payload for each of a plurality of data streams (audio, video), the payload being encrypted and having an arbitrary block size, and having a payload header for each payload and including a boundary for the arbitrary block size. Each enhanced RTP packet includes only one data stream (audio or video), corresponds to one of the mixed media packets, and includes a payload corresponding to one of the payloads in one mixed media packet, a payload profile format header (RTP PF) corresponding to the one payload, and one or more payload headers of the one mixed media packet. The payload profile format header has a boundary corresponding to the respective boundaries of the one or more payload headers of the one mixed media packet and the one payload.
Patent NZ-548119-A (NZ)
Title: A set of construction panels and building construction method
Inventor: MCINTYRE DARREN
IPC: E04B2/44
Filed: 2004-11-26
Abstract: A set of double panels for building construction, where each double panel has a base, a top, two end walls, a pair of parallel side walls, and at least one cavity 23 between the side walls that extends the full height of the panel, and where each of the end walls has a key slot that extends the height of the panel for joining to other panels. Each of the panels has the base and the top formed with one of the following distal portions:- 1. A substantially flat distal portion including the side walls where each of the side walls comprises a longitudinal recess; 2. A distal portion with the side walls protruding to form a U-shaped channel where each of the side walls comprises a longitudinal recess; 3. A distal portion including a protruding side wall that forms an L-shaped ledge where the protruding side wall comprises a longitudinal recess.
Patent NZ-550185-A (NZ)
Title: Methods of inducing terminal differentiation Methods of inducing terminal differentiation
Inventor: RICHON VICTORIA M
IPC: A61K31/4709
Filed: 2003-03-04
Abstract: Disclosed is a method for preparing suberoylanilidDisclosed is a method for preparing suberoylanilide hydroxamic acid (SAHA) comprising the step of ree hydroxamic acid (SAHA) comprising the step of recrystallising a crude preparation of SAHA from a mcrystallising a crude preparation of SAHA from a mixture of methanol and water. Also disclosed is thixture of methanol and water. Also disclosed is the crystalline form of SAHA obtained by that methode crystalline form of SAHA obtained by that method, and pharmaceutical compositions comprising it.  , and pharmaceutical compositions comprising it.
Patent NZ-553273-A (NZ)
Title: Treating gliosis, glial scarring, inflammation or inhibition of a xonal growth in the nervous system with an antagonist of EphA4-mediated signalling
Inventor: BARTLETT PERRY F
IPC: A61K31/7105
Filed: 2005-09-08
Abstract: Disclosed is the use of an antagonist of EphA4-mediated signalling in the manufacture of a medicament for preventing or reducing the amount of gliosis and/or glial scarring in the nervous system of a subject.
Patent NZ-563763-A (NZ)
Title: Hydratable keratin compositions
Inventor: WU CHUNYONG
IPC: A61K35/36
Filed: 2006-05-04
Abstract: Provided is a composition comprising an absorbent keratin material obtained from a hair filament, wherein the absorbent material is substantially free of water soluble keratin proteins and peptides and wherein the material is produced by saturating the filament with aqueous solvent to obtain an expanded filament and subsequently removing the water by sublimation to obtain an absorbent material. The material if useful for water absorbent films, bandages or environmental liquid absorbents.
Patent NZ-569371-A (NZ)
Title: A method of controlling the aquatic weed hydrilla verticillata using Imazamox
Inventor: ZAWIERUCHA JOSEPH
IPC: A01N43/42
Filed: 2006-12-18
Abstract: Disclosed is a method of controlling the aquatic weed Hydrilla verticillata which comprises allowing a herbicidally effective amount of (RS)-2-(4-isopropyl-4-methyl-5-oxo-2-5 imidazolin-2-yl)-5-methoxymethylnicotinic acid (imazamox) or an agriculturally acceptable salt thereof to act on the aquatic weed and/or its aqueous habitat containing seeds or other propagating organs of said aquatic weed.
Patent NZ-571337-A (NZ)
Title: Process for preparing human G-CSF
Inventor: MENDIRATTA SANJEEV KUMAR
IPC: C07K14/535
Filed: 2007-03-05
Abstract: Disclosed is a process for obtaining high volumetric yields of Granulocyte Colony Stimulating Factor (G-CSF) comprising: i) inoculating a fermenter with a recombinant E.coli strain previously transformed with an expression vector encoding gene of G-CSF; ii) culturing of recombinant E.coli through pre-production and production phase of fermentation to express G-CSF gene product in a culture broth, wherein the culture broth comprises K ions in the concentration range of substantially 60 mM to substantially 180 mM in combination with high concentration of inorganic cations selected from Na ions in the range of substantially 90 mM to substantially 300 mM, and Mg ions in the range of substantially 150 mM to substantially 250 mM.
Patent NZ-578609-A (NZ)
Title: A modular plastic pelt pallet former having a rear and side walls with swinging front doors
Inventor: WALLACE BRIAN
IPC: C14C15/00
Filed: 2010-04-12
Abstract: A modular pallet former for processing ovine pelts is disclosed. The pallet former comprises first and second side panels, a rear panel, and two or more swinging doors, where the side and rear panels and doors are formed from plastic. A first edge of each of the side panels is interlocked with a respective edge of the rear panel. The side and rear panels fit around three of the edges of a generally rectangular base to form a generally rectangular container in which the pelts can be stacked. The container has opposed sides formed by the side panels, a rear side formed by the rear panel, a floor formed by the base, an open top and an open front side, and two or more swinging doors. Each door has first and second swinging door panels. The first edges of the first and second door panels of each door are interlocked with second edges of respective side panels to form hinges so the door panels of each door can swing in a generally horizontal plane between at least an open condition that facilitates stacking the pelts in the container and a closed condition in which the door at least partially closes the front side. The swinging doors are located one above the other so the panels of each door can swing independently of the panels of the other door(s). Adjacent second edges of the door panels of each door, when the door is in the closed position, can be interlocked to one another to retain the door in the closed position.
Patent NZ-580135-A (NZ)
Title: Cultured dairy products and methods of manufacture
Inventor: SWELEY JESS C
IPC: A23C9/12
Filed: 2009-10-02
Abstract: Provided is a process for the manufacture of a cultured dairy product containing cultured and non-cultured dairy ingredients, said process comprising (1) providing a first mixture of dairy ingredients having a first amount of dairy protein; (2) homogenizing and pasteurizing the first mixture to form a homogenized and pasteurized first mixture; (3) cooling the homogenized and pasteurized first mixture to about 20 C° to about 40 C° to form a cooled first mixture; (4) adding a lactic acid-producing bacterial culture to the cooled first mixture, after cooling to form a culture containing first mixture; (5) culturing the culture-containing first mixture at a temperature and for a time sufficient to obtain a pH-stable cultured first mixture, wherein the stable pH is in the range of about 3.5 to about 5.5; (6) providing a second mixture of dairy ingredients having a second amount of dairy protein, salts, and gums; (7) adding the second mixture to the pH-stable cultured first mixture to form a third mixture; and (8) heating and homogenizing the third mixture at a temperature and for a time sufficient to obtain a cultured dairy product containing cultured and non-cultured dairy ingredients, having a total amount of dairy protein; wherein the first amount of dairy protein is about 10 to about 40 percent and the second amount of dairy protein is about 60 to about 90 percent, based on the total amount of dairy protein, wherein the cultured dairy product has a whey protein to casein ratio from 42:58 to 45:55, and wherein the process does not include a whey-separation step.
Patent NZ-586775-A (NZ)
Title: 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
Inventor: BEARD RICHARD L
IPC: C07D209/42
Filed: 2008-07-10
Abstract: Disclosed are indole- amide compounds represented by general formula (I). The compounds are used to treat glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, and wound healing.
Patent NZ-587047-A (NZ)
Title: Valved luer cone connector for medical lines with freely rotatable threaded coupling.
Inventor: GUALA GIANNI
IPC: A61M39/26
Filed: 2009-01-23
Abstract: A valve connector (1) for medical lines comprising a tubular body (2) having a male inlet fitting (3) with external luer cone (14), which can be coupled to a female tubular fitting (5) with internal luer cone (8). The inlet fitting (3) comprises an internally threaded external tubular element (10) for screwed engagement with the female fitting (5), and an internal tubular element (12). The internal tubular element can be displaced axially from a retracted position of closing to an advanced position of opening the valve means that control the passage of flow through the connector (1). The internally threaded external tubular element (10) is free to turn with respect to the internal tubular element. The arrangement is such that when the threaded tubular element is screwed off the female fitting (5) the passage of flow is closed by the valve means while the external luer cone (14) and the internal luer cone (8) remain axially coupled to one another by friction.
Patent NZ-590774-A (NZ)
Title: Substantially pure 5R enantiomers of pioglitazone and rosiglitazone for treating inflammatory respiratory diseases
Inventor: FINCH HARRY
IPC: A61K9/00
Filed: 2009-08-05
Abstract: Disclosed is the use of a glitazone in the preparation of a medicament for the treatment of inflammatory respiratory disease by pulmonary administration by inhalation, wherein said disease is selected from mild asthma, moderate asthma, severe asthma, steroid resistant asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary edema, pulmonary embolism, pneumonia, pulmonary sarcoidosis, silicosis, pulmonary fibrosis, respiratory failure, acute respiratory distress syndrome, emphysema, chronic bronchitis, tuberculosis, and lung cancer, wherein the glitazone is pioglitazone or rosiglitazone and the glitazone content of the medicament consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer.
Patent NZ-591104-A (NZ)
Title: Trigger-operated portable electric tool
Inventor: PELLENC ROGER
IPC: A01G3/037
Filed: 2009-08-19
Abstract: A trigger-operated portable electric tool that is designed to perform a main function such as pruning. The tool includes a double trigger (5-6) consisting of a main trigger (5) which operates at least one moving active part (3) of the tool and an auxiliary trigger or secondary trigger (6) connected to the main trigger by means of an articulation (7) and designed to make an angle with the main trigger. The pivoting of the auxiliary trigger about the articulation enables actuation of a means (8) of operating a system designed to perform at least one additional function of the tool.
Patent NZ-593692-A (NZ)
Title: Transgenic plants containing soluble cell wall polysaccharides
Inventor: SHOSEYOV ODED
IPC: A01H5/00
Filed: 2008-03-26
Abstract: Disclosed is a method of making a biofuel product comprising: a) Over-expressing a nucleic acid molecule encoding glutamine:fructose 6-phosphate aminotransferase (GFAT) in a plant; and b) Processing the cellulose or hemicellulose portion of the plant into said product. Further disclosed is a biofuel product produced by said method, such as ethanol, butanol, xylose, mannose, arabinose, galactose or glucose.
Patent NZ-594695-A (NZ)
Title: NEW MARKER FOR DIAGNOSIS OF ACTIVE MULTIPLE SCLEROSIS by IL-23p19 and IL-1 beta
Inventor: STORDEUR PATRICK
IPC: G01N33/50
Filed: 2010-03-25
Abstract: 594695 NEW MARKER FOR DIAGNOSIS OF ACTIVE MULTIPLE SCLEROSIS by IL-23p19 and IL-1 beta Provided is method for predicting, diagnosing and/or prognosticating Multiple Sclerosis (MS) in a subject, using the ratio of the level of IL-23p19 before and after stimulation with an immune-modulator, correlated with the ratio of the level of IL-1-beta before and after stimulation with an immune-modulator and comparing the obtained relation to a reference value calculated based on the cytokine levels in a sample from a subject having non-active MS or no MS.
Patent NZ-596331-A (NZ)
Title: Methods of structuring data, pre-compiled exception list engines, and network appliances
Inventor: MAESTAS DAVID
IPC: H04L29/12
Filed: 2010-04-19
Abstract: A network appliance for connection to a first network and a second network is disclosed. The appliance comprises at least one input coupled to the first network for receiving a data packet from the first network; at least one memory device storing instructions and data and at least one processor executing computer-executable instructions. The data packet includes an internet protocol (IP) address. The data includes a plurality of pages storing a plurality of excepted IP addresses. The excepted IP addresses each have a numeric value within a range and the range is divided into a plurality of contiguous sub-ranges. Each page includes one or more of the excepted IP addresses having numeric values within one or more of the sub-ranges associated with that page. Each page has a page size defined by the number of IP addresses assigned to that page, the IP addresses assigned to each page ordered by numeric value. The computer-executable instructions are to identify the IP address of the packet from the first network; identify a target page that will include the IP address if the IP address is one of the plurality of excepted IP addresses; search the target page to determine if the IP address is one of the excepted IP addresses in the target page; process the packet from the first network according to whether the IP address is an excepted IP address in the target page; determine whether to allow or deny the data packet from the first network to proceed to the second network based on the IP address not being an excepted IP address in the target page.
Patent NZ-598813-A (NZ)
Title: An intrauterine system
Inventor: TJADER TAINA
IPC: A61F6/14
Filed: 2010-09-30
Abstract: The disclosure relates to intrauterine systems and to methods for manufacturing these systems. An intrauterine system according to the invention comprises a reservoir and a continuous, closed and flexible frame of polygonal shape. The frame comprises a thermoplastic polyurethane elastomer made of a polycarbonate diol, 1,6-hexamethylene diisocyanate, and a chain extender.
Patent NZ-602411-A (NZ)
Title: Manual operation of a door opener
Inventor: PATTERSON SHANE
IPC: E05F15/10
Filed: 2012-09-13
Abstract: An electric motor driven door or barrier opener is disclosed with a manually operable drive for use in a power failure. The opener comprises a gear box connectable with an electric motor and with an output drive for coupling with a door or barrier. A shaft (25) is rotated by the output drive when the motor rotates. The shaft (25) carries a freewheeling manual drive wheel (9) with at least one drive coupling pin (203) biased toward a disengagement position when the manual drive wheel (9) is not rotated. When there is a manual rotation of the drive wheel (9) the manual rotation will move the coupling pin (203) in a radial direction to couple the drive wheel (9) and the shaft (25) to permit manual opening or closing of the door or barrier. Movement of the coupling pin (203) is effected by a cam surface within a passageway (209) in the manual drive wheel (9).
Patent NZ-607970-A (NZ)
Title: Wave energy conversion
Inventor: FIEVEZ JONATHAN PIERRE
IPC: F04B9/02
Filed: 2011-08-16
Abstract: Wave energy conversion system including a buoyant apparatus (14); and a pump (15) for extracting energy from wave motion. Operatively connectable the pump (15) by way of coupling (18) which includes the tether (19). The buoyant apparatus comprises a hollow body which presents an exterior surface adapted to be continuously located below the surface of the water (12a) during operation. A damping means is connects the hollow body to a tether (19). The damping means provides a yieldingly resilient connection between the hollow body and the tether (19).
Patent NZ-609765-A (NZ)
Title: Uses of dpp-iv inhibitors
Inventor: DUGI KLAUS
IPC: A61K31/4985
Filed: 2007-05-03
Abstract: Disclosed is the use of a DPP IV inhibitor linagliptin also known as 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione or 1-[( 4-methyl-quinazolin-2-yl)methyl]-3-methyl-7 -(2-butyn-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine for preparing a medicament for the therapeutic treatment of a physiological functional disorder heart failure. Also disclosed is the combination of linagliptin with another active for the treatment of type 2 diabetes, pre-diabetes or metabolic syndrome. Examples of the other active includes metformin, telmisartan and glitazone. The dosage of linagliptin is 2.5 mg or 5 mg and the dosage is for oral administration.